HQ Team
March 18, 2026: Switzerland’s F. Hoffmann-La Roche AG upgraded its artificial intelligence infrastructure by deploying Nvidia’s technology to accelerate development of diagnostic solutions and therapeutics.
The healthcare multinational increased its computing capacity by installing a large-scale AI factory powered by a full stack of the latest-generation Nvidia accelerated computing, featuring 2,176 high-performance graphics processing units (GPUs), in the US and Europe.
The AI expansion “is the greatest announced GPU footprint available to a pharmaceutical company,” according to a company statement.
“In healthcare, time is the most critical variable; every day saved means a life-changing medicine or diagnostic reaches a patient sooner,” said Wafaa Mamilli, Roche’s Chief Digital and Technology Officer.
“Our AI factory combines world-class computing power with Roche’s scientific expertise to embed AI across the entire value chain — from discovery to development, manufacturing and commercialisation — transforming how we deliver the next generation of medicines and diagnostics solutions.”
Improved healthcare outcomes
Nvidia’s AI factories help accelerate discoveries, enable more efficient clinical trials, and unlock data insights at scale, ultimately advancing innovation and improved healthcare outcomes.
Roche’s collaboration with Nvidia started in 2023. The pact will help accelerate Roche’s“lab in a loop,” where extensive experimental data feeds computational models that uncover patterns and make new, experimentally testable predictions.
Scientists quickly assess these predictions in the lab, and the results are fed back into the models to improve the underlying computational model, allowing for iterative development of better therapies.
In manufacturing, digital twins — virtual replicas of production lines — powered by Nvidia Omniverse libraries, allow engineers to optimise processes and factory designs.
Detect disease patterns
For diagnostics, accelerated computing and Nvidia’s software enable insights across vast datasets and in digital pathology, the technologies scan a large number of images to detect subtle disease patterns.
In digital health, Roche uses Nvidia NeMo Guardrails to ensure safe and reliable healthcare-grade conversational AI.
“By providing the massive computational power needed to continue to scale our lab-in-the-loop strategy — a space we have pioneered for over five years — our scientists can build more sophisticated predictive frontier models and further shorten the path from biological insight to life-saving medicine,” said Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development.
Genentech is a wholly owned subsidiary and member of the Roche Group. Roche, a Swiss healthcare company, completed the acquisition of Genentech in March 2009 for approximately $46.8 billion.
Explosive growth
Autonomous artificial intelligence systems, or agentic AI, are capable of pursuing complex goals with limited supervision by planning, reasoning, and taking multi-step actions.
Unlike passive generative AI, these systems use agents to interact with software, tools, and environments, acting as ‘digital employees’ to automate workflows in customer service, coding, and analytics.
According to Mordor Intelligence, the agentic AI market size was valued at $6.96 billion in 2025 and is estimated to grow from $9.89 billion in 2026 to reach $57.42 billion by 2031.
